Angiex, Inc.

Angiex Achieves Major Safety Milestone

About this Event

Angiex is developer of first-in-class Nuclear-Delivered Antibody-Drug Conjugates with the potential to treat all solid tumor cancers, recently announced their lead program, AGX101, has safely cleared two dose levels expected to demonstrate efficacy. As a result, Angiex is initiating an expansion in visceral angiosarcoma which the company expects to be its first approved indication. Visceral angiosarcoma is a high unmet need indication with only a 5-9% response rate and 3 month progression-free survival on the second line of therapy. 

AGX101 is a nuclear delivered ADC that has the largest preclinical therapeutic margin ever seen in an oncology drug, indicating potential for unprecedented safety. It is a true “magic bullet,” delivering a ten-fold higher fraction of injected drug to the tumor than other treatments.

Currently, AGX101 has entered Phase 1 clinical trials, and early results are promising. Given its unique mechanism and broad applicability across various cancer types, AGX101 has significant commercial potential. Angiex not only has the vision that no one should die of cancer, it has the practical means to achieve its vision.

Register now to watch Angiex founder and CEO, Paul Jaminet explain why their drug, AGX101, has the potential to treat a wide range of solid tumor cancers including pancreatic, lung, liver, ovarian, cervical, bladder, and more.

Video On Demand

– Recorded

March 20

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.